Abbvie ((ABBV)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: AbbVie recently completed a study titled A Study to Assess the Effect of Food on ABBV-101 Pharmacokinetics When Administered as an Oral ABBV-101 Tablet Formulation in Healthy Volunteers. The study aimed to understand how a high-fat meal affects the movement of the drug ABBV-101 through the body, which is crucial for optimizing its administration and effectiveness.
Intervention/Treatment: The intervention tested was the drug ABBV-101, administered orally in tablet form. The study explored its pharmacokinetics under fasting and non-fasting conditions to determine the impact of food intake.
Study Design: This Phase 1 interventional study employed a randomized, crossover design with no masking. Participants were divided into two groups, receiving the drug under different conditions to compare its movement through the body.
Study Timeline: The study began on March 14, 2025, and was last updated on September 29, 2025. These dates are vital for tracking the study’s progress and ensuring timely updates to stakeholders.
Market Implications: The completion of this study could influence AbbVie’s stock performance by providing insights into ABBV-101’s administration, potentially enhancing its marketability. Investors should watch for further developments, especially in comparison to competitors exploring similar pharmacokinetic studies.
The study is completed, with further details available on the ClinicalTrials portal.